Skip to main content
Premium Trial:

Request an Annual Quote

RenalytixAI, AstraZeneca Ink Agreement to Enhance Chronic Disease Patient Outcomes

NEW YORK – RenalytixAI and AstraZeneca have signed an agreement to develop and launch precision medicine strategies for cardiovascular, rental, and metabolic diseases.

Working with the Mount Sinai Health System, the firms plan to use RenalytixAI's KidneyIntelX platform to help improve outcomes for patients with chronic kidney disease (CKD) and its complications.

RenalytixAI's KidneyIntelX generates a risk score of a patient's progressive kidney decline by combining data from their electronic medical record and measuring three well-known biomarkers predictive of kidney disease in their blood or urine sample.

The team initially aims to help improve guideline-based standard-of-care for optimal use of existing and novel therapeutics using KidneyIntelX and proprietary care management software.

The firms will also evaluate the impact of AI-enabled in vitro diagnostic tools to optimize therapy use in CKD under current standard-of-care protocols. Based on the study's outcomes, the group will launch a multi-center, randomized controlled trial to measure uptake and adherence to potassium-binding agents in patients with CKD and hyperkalemia.

The team anticipates results from the studies, which will be performed in coordination with Mount Sinai, in early 2021.

"We believe this collaboration will define how we can leverage KidneyIntelX to improve the care and outcomes for patients affected by chronic diseases," Barbara Murphy, dean for clinical integration and population health management at the Icahn School of Medicine and Mount Sinai and board member at RenalytixAI, said in a statement. "By using a more personalized approach, our initial goal is to help realize improved outcomes for more than 240,000 patients with [CKD] within the Mount Sinai Health System."

Financial details of the agreement were not disclosed.

"We are committed to revolutionizing kidney care by continuing to drive innovation," Tarek Rabah, VP of AstraZeneca US Renal-Cardio, said in a statement. "An important component of our work is identifying patients with significant unmet need and providing them with more personalized intervention."